MEP26408A - Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics - Google Patents

Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

Info

Publication number
MEP26408A
MEP26408A MEP-264/08A MEP26408A MEP26408A ME P26408 A MEP26408 A ME P26408A ME P26408 A MEP26408 A ME P26408A ME P26408 A MEP26408 A ME P26408A
Authority
ME
Montenegro
Prior art keywords
group
compounds
hydrogen atom
cycloalkyl
general formula
Prior art date
Application number
MEP-264/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Ahmed Abouabdellah
Garcia Antonio Almario
Jacques Froissant
Christian Hoornaert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MEP26408A publication Critical patent/MEP26408A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
MEP-264/08A 2004-01-16 2005-01-07 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics MEP26408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400389A FR2865205B1 (fr) 2004-01-16 2004-01-16 Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
PCT/FR2005/000028 WO2005077898A1 (fr) 2004-01-16 2005-01-07 Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MEP26408A true MEP26408A (en) 2010-06-10

Family

ID=34707893

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-264/08A MEP26408A (en) 2004-01-16 2005-01-07 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

Country Status (29)

Country Link
US (3) US7439257B2 (es)
EP (1) EP1708994B1 (es)
JP (1) JP4705590B2 (es)
KR (1) KR101171462B1 (es)
CN (1) CN100537534C (es)
AR (1) AR047384A1 (es)
AT (1) ATE369336T1 (es)
AU (1) AU2005212868B2 (es)
BR (1) BRPI0506918A (es)
CA (1) CA2552565C (es)
CY (1) CY1106918T1 (es)
DE (1) DE602005001930T2 (es)
DK (1) DK1708994T3 (es)
ES (1) ES2289701T3 (es)
FR (1) FR2865205B1 (es)
HK (1) HK1101283A1 (es)
HR (1) HRP20070421T3 (es)
IL (1) IL176769A (es)
MA (1) MA28343A1 (es)
ME (1) MEP26408A (es)
NO (1) NO20063681L (es)
NZ (1) NZ548530A (es)
PL (1) PL1708994T3 (es)
PT (1) PT1708994E (es)
RS (1) RS50518B (es)
RU (1) RU2392269C2 (es)
TW (1) TWI402067B (es)
WO (1) WO2005077898A1 (es)
ZA (1) ZA200605698B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) * 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
KR101063585B1 (ko) 2005-02-17 2011-09-07 아스텔라스세이야쿠 가부시키가이샤 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체
US8197472B2 (en) 2005-03-25 2012-06-12 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US7918848B2 (en) 2005-03-25 2011-04-05 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
WO2009019534A2 (en) 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
KR20090097184A (ko) * 2006-12-06 2009-09-15 스미스클라인 비참 코포레이션 비시클릭 화합물 및 항당뇨병제로서의 용도
CL2008002384A1 (es) * 2007-08-15 2009-07-17 Glaxo Group Ltd Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
JP2011500634A (ja) * 2007-10-16 2011-01-06 グラクソ グループ リミテッド 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体
US9968396B2 (en) 2008-05-27 2018-05-15 Maquet Cardiovascular Llc Surgical instrument and method
US9402680B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovasular, Llc Surgical instrument and method
JP2011521723A (ja) 2008-05-27 2011-07-28 マッケ カーディオバスキュラー，エルエルシー 外科用器具および方法
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
US9955858B2 (en) * 2009-08-21 2018-05-01 Maquet Cardiovascular Llc Surgical instrument and method for use
KR20120125302A (ko) * 2010-01-20 2012-11-14 사노피 알킬-헤테로사이클 카르바메이트 유도체, 그의 제조법 및 그의 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1039902B1 (en) * 1997-11-24 2006-03-08 The Scripps Research Institute Inhibitors of gap junction communication
WO1999052493A2 (en) * 1998-04-16 1999-10-21 Texas Biotechnology Corporation Compounds that inhibit the binding of integrins to their receptors
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
IL158300A0 (en) * 2001-04-27 2004-05-12 Bristol Myers Squibb Co Bisarylimidazol derivatives and pharmaceutical compositions containing the same
AU2003210824A1 (en) 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EA010267B1 (ru) * 2002-10-07 2008-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Модуляция тревоги через блокаду гидролиза анандамида
AU2003275493A1 (en) * 2002-10-08 2004-05-04 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
FR2850377B1 (fr) * 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US7674805B2 (en) 2010-03-09
TW200536524A (en) 2005-11-16
EP1708994A1 (fr) 2006-10-11
MA28343A1 (fr) 2006-12-01
DE602005001930D1 (de) 2007-09-20
NZ548530A (en) 2010-02-26
FR2865205A1 (fr) 2005-07-22
TWI402067B (zh) 2013-07-21
RU2006129640A (ru) 2008-02-27
DK1708994T3 (da) 2007-11-26
WO2005077898A1 (fr) 2005-08-25
PT1708994E (pt) 2007-10-02
KR101171462B1 (ko) 2012-08-07
BRPI0506918A (pt) 2007-06-05
KR20070000478A (ko) 2007-01-02
ZA200605698B (en) 2007-11-28
CN100537534C (zh) 2009-09-09
AR047384A1 (es) 2006-01-18
NO20063681L (no) 2006-09-18
JP4705590B2 (ja) 2011-06-22
US7439257B2 (en) 2008-10-21
US8026258B2 (en) 2011-09-27
PL1708994T3 (pl) 2008-01-31
HRP20070421T3 (en) 2007-10-31
DE602005001930T2 (de) 2008-04-30
JP2007522111A (ja) 2007-08-09
FR2865205B1 (fr) 2006-02-24
ATE369336T1 (de) 2007-08-15
US20100120845A1 (en) 2010-05-13
IL176769A (en) 2010-06-30
CA2552565A1 (fr) 2005-08-25
AU2005212868B2 (en) 2011-04-21
RU2392269C2 (ru) 2010-06-20
EP1708994B1 (fr) 2007-08-08
US20070021424A1 (en) 2007-01-25
RS50518B (sr) 2010-05-07
ES2289701T3 (es) 2008-02-01
IL176769A0 (en) 2006-10-31
US20080312262A1 (en) 2008-12-18
CY1106918T1 (el) 2012-09-26
CN1922138A (zh) 2007-02-28
CA2552565C (fr) 2013-12-31
AU2005212868A1 (en) 2005-08-25
HK1101283A1 (en) 2007-10-12

Similar Documents

Publication Publication Date Title
MEP26408A (en) Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
CO4950619A1 (es) Derivados de acido arilsulfonil hidroxamico
DK0956855T3 (da) Immunhæmmende effekter af 8-substituerede xanthin-derivater
BR0008759A (pt) Métodos para a produção de proteinas contendo resìduos de cisteina livre
ES2063094T3 (es) Derivados de oximeter, procedimiento para su obtencion y fungicidas que les contienen.
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
MY126736A (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
JP2007537275A5 (es)
HUP0400159A2 (hu) Heteroarilszulfonil-oldalláncot hordozó antranilsavamid-származékok, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR9901298A (pt) Novos compostos de benzotiofeno, benzofurano e indol, um processo para sua preparação e composições farmacêuticas que os contêm
DE69423802T2 (de) Indolderivate als 5-HT1-like Agonisten
RS49906B (sr) Benzociklohepteni, postupak za njihovo dobijanje, farmaceutski preparati koji ove sadrže kao i njihova primena za izradu lekova
NO20021001L (no) Radiofarmasöytiske produkter og fremgangsmåter for fremstilling derav
RU2005111590A (ru) 2,4-замещенные индолы и их использование в качестве модуляторов 5-гт6
NO158578C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater.
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
IT7868405A0 (it) Procedimento e sistema per la conversione in idrogeno solforato dell'anidride solforosa contenuta nei gas di camino e simili
FR2803593B1 (fr) Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
RS51246B (sr) Derivati heteroarila-alkilkarbamata, njihovo dobijanje i njihova primena kao inhibitora faah enzima
ES2065901T3 (es) Derivados de piridazinona y composiciones para reprimir y/o prevenir plagas de insectos.
BR0015167A (pt) Naftopiranos possuindo um substiiuinte perfluoroalquil na posição 5, preparação e composições e matrizes contendo-os
DE60312953D1 (de) Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
AR002259A1 (es) Derivados de 1-oxo-2-(fenilsulfonilamino)pentilpiperidina, su preparacion, compuestos intermedios y composicion que contiene a dichos derivados.
ATE259775T1 (de) 3-bicycloaryl-2-aminomethyl bicycloalkane als serotoniner reuptake inhibitor
ES8201541A1 (es) Un procedimiento para la preparacion de nuevas guanilamidi- nas